Shay Capital’s Cytokinetics CYTK Stock Holding History

Shay Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,500	Closed	-$1.46M	–	399
2023 Q4	$1.46M	Buy	+17,500	New	+$634K	0.29%	62

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Shay Capital's CYTK Position: Q2 2026 in Review

Shay Capital sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 3,275 shares — an estimated $216K sold.

Shay Capital first reported a position in CYTK in Q4 2023 and held it in 10 quarters. The position peaked at $3.16M in Q4 2023. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Shay Capital reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
Shay Capital sold 3,275 Cytokinetics shares in Q2 2026, an estimated $216K.
Shay Capital first reported a position in Cytokinetics in Q4 2023 and held it in 10 quarters.
Shay Capital's Cytokinetics position peaked at $3.16M in Q4 2023.
484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.